BC Week In Review | Jun 30, 2014
Company News

Edimer, InformedDNA deal

Informed Medical Decisions (InformedDNA) developed a genetic counseling program for patients and families affected by X-linked hypohydrotic ectodermal dysplasia (XLHED) in which InformedDNA may identify individuals that may benefit from treatment with Edimer’s EDI200 . As...
BC Week In Review | Oct 14, 2013
Clinical News

Fc-EDA1: Phase II started

Edimer began an open-label, dose-escalation, international Phase II trial to evaluate 3 and 10 mg/kg EDI200 in about 6 male newborns with XLHED. Dosing will begin between days 2 and 14 after birth with each...
BC Extra | Jul 31, 2013
Financial News

Edimer secures $18M in series B

Edimer Pharmaceuticals Inc. (Cambridge, Mass.) secured $18 million in a tranched series B round led by new investor New Enterprise Associates (NEA). New investor Sanofi-Genzyme BioVentures also participated, along with existing investors Third Rock Ventures...
BioCentury | Aug 27, 2012
Emerging Company Profile

Edimer: Gland idea

Unlike enzyme replacement therapies that are taken chronically for life, Edimer Pharmaceuticals Inc. hopes a single course of its EDI200 given either before or soon after birth will permanently correct a rare developmental disorder. The...
BC Week In Review | Jun 18, 2012
Clinical News

Fc-EDA1 regulatory update

FDA granted Fast Track designation for Edimer's EDI200 to treat X-linked hypohidrotic ectodermal dysplasia (XLHED). EDI200 is a recombinant protein comprised of the Fc domain of human IgG1 and tumor necrosis factor (TNF) domain of...
BioCentury | Mar 15, 2010
Finance

Ebb & Flow

A number of smart investors are placing bets that gene therapy will finally work. Third Rock Ventures led a $35 million series B round for Genetix Pharmaceuticals Inc. last week. The round included one new...
BC Week In Review | Apr 16, 2007
Company News

Apoxis, Topotarget deal

TOPO will acquire Apoxis for E14.5 million ($19.4 million) in stock. Apoxis’ shareholders will provide Apoxis with a E4 million ($5.3 million) convertible loan prior to the deal’s close and will be eligible for more...
BC Week In Review | Feb 6, 2006
Clinical News

APO200 regulatory update

FDA granted Orphan Drug designation to APO200 to treat X-linked hypohidrotic ectodermal dysplasia (XLHED). The recombinant form of ectodysplasin A gene (EDA1) on the X chromosome also has Orphan Drug designation in Europe. Apoxis expects...
Items per page:
1 - 8 of 8